Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary) ; Posaconazole (Primary) ; Posaconazole (Primary) ; Voriconazole (Primary) ; Voriconazole (Primary)
- Indications Bacterial infections; Mycoses
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 10 Sep 2019 Planned End Date changed from 1 Feb 2021 to 1 Apr 2020.
- 10 Sep 2019 Planned primary completion date changed from 1 Feb 2021 to 1 Apr 2020.
- 06 May 2019 Status changed from recruiting to active, no longer recruiting.